Matt is a member of Newton’s equity research team. Matt is responsible for covering the healthcare sector, specifically biopharmaceutical and medical-technology companies, and managing portfolios in the Smart Cures Innovation strategy.

Joined industry
Joined the Group

Matt joined Newton in September 2021, following the integration of Mellon Investments Corporation’s equity and multi-asset capabilities into the Newton Investment Management Group. Before joining Newton, Matt was a senior research analyst at Mellon Investments Corporation and The Boston Company Asset Management (both BNY Mellon group companies).

Prior to joining BNY Mellon, Matt served as a portfolio manager and analyst covering the healthcare sector at Balyasny Asset Management. Prior to that, he managed global long/short equity healthcare hedge funds and covered the pharmaceuticals, biotechnology and healthcare services industries at Lehman Brothers/Barclays Capital. Prior to joining the investment industry, Matt was a senior research scientist at SmithKline Beecham.

Matt has a BS in Biology from Tulane University and an MBA from New York University.